What is IMNN's current stock price?

IMNN (Imunon, Inc.) is currently trading at $2.20 with a market cap of $5.5M.

What sector is Imunon, Inc. in?

Imunon, Inc. (IMNN) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IMNN a good stock to buy?

Analysts have a Buy consensus on IMNN with a price target of $10.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IMNN Imunon, Inc.

Healthcare

$2.20+2.33%ClosedMarket Cap: $5.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.29

P/S

0.00

EV/EBITDA

-0.12

DCF Value

$3.08

FCF Yield

-271.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-341.2%

ROA

-182.6%

ROIC

-346.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-4.2M	$—
Q4 null	$0.00	$-4.2M	$—
FY null	$0.00	$-14.5M	$—
Q3 null	$0.00	$-3.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$10.00

Target (Median)

$10.00

Target Range

$10.00 - $10.00

1 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

CHURCH JEFFREY WAYNEofficer: CFO

SellTue Jan 20

CHURCH JEFFREY WAYNEofficer: CFO

SellTue Jan 20

CHURCH JEFFREY WAYNEofficer: CFO

SellTue Jan 20

Pellizzari Christine Adirector

SellTue Jan 06

Fritz Frederick J.director

SellTue Jan 06

Latest News

IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian CancerGlobeNewsWire · Wed Mar 25

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.03

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

Peers